Startseite Kongressberichte & Archiv 2021 ASCO Annual Meeting Haematological Malignancies Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

 
Jorge E. Cortes, Jane Apperley, Elza Lomaia, et al.
The study authors present the OPTIC primary analysis which shows an optimal benefit:risk profile for ponatinib with a response-based dosing regimen starting with 45 mg/d, followed by dose reduction to 15 mg/d upon achieving ≤1% BCR-ABL1IS; 30 mg→15 mg and 15 mg cohorts may provide benefit, especially in pts without T315I mutation (see Table in the abstract). Robust survival outcomes were observed in patients with CP-CML resistant to second-generation BCR-ABL1 TKI therapy with/without BCR-ABL1 mutations. Clinical trial information: NCT02467270
 
 
Nicholas James Short, Hagop M. Kantarjian, Marina Konopleva,et al.
The study authors conclude, that the chemotherapy-free combination of ponatinib and blinatumomab shows encouraging results in Ph+ ALL. It results in high rates of complete molecular remission and durable responses. This potentially obviates the need for chemotherapy and AHSCT in many patients, particularly in frontline therapy. Clinical trial information: NCT03263572
 
 
Bijal D. Shah, Armin Ghobadi, Olalekan O. Oluwole, et al.
The study authors conclude, that after a median follow-up of 16.4 mo, KTE-X19 demonstrated compelling clinical benefit in heavily pretreated adults with R/R B-ALL. The median overall survival was not yet reached for responding patients. A manageable safety profile was observed. Clinical trial information: NCT02614066
 
 
Taiga Nishihori, Qaiser Bashir, Marcelo C. Pasquini, et al.
The study authors conclude, that AlloHCT with reduced intensity fludarabine/melphalan and a single pre-HCT dose of bortezomib is safe and can produce durable disease control in extremely high-risk patients. Because of the early termination of the study ixazomib maintenance after alloHCT could not be assessed. Clinical trial information: NCT02440464
 
 
Delaney Wolfe, Qiuhong Zhao, Emma G Siegel, et al.
The study authors conclude, that  prophylaxis with the viral terminase inhibitor Letermovir significantly decreased clinically significant CMV infection and improved non-relapse mortality and overall survival in this real-world analysis. Patients with acute GVHD had significantly less CMV viremia. This suggests a potential benefit in continuing letermovir prophylaxis in this patient population.
 
 
Emily Walsh, Anastasia Tsakmaklis, Liyang Diao, et al.
The study authors show data from this observational study (COLLECT) which suggest decreases in microbial diversity over time in subjects undergoing allogeneic HSCT despite the lack of prophylactic antibiotics. Clinical trial information: NCT03148197
 
 
Stéphane De Botton, Karen W. L. Yee, Christian Recher, et al.
Olutasidenib, a potent, selective, oral, small-molecule inhibitor of mutant IDH1 (mIDH1). The study authors conclude, that this drug was well tolerated and induced durable complete remission in a subset of high-risk R/R mIDH1 AML pts. TI was achieved in all response groups. There was a clinical benefit, per duration of response and overall survival, extended beyond complete remission (CR) responders or CR with partial hematologic recovery responders. Clinical trial information: NCT02719574
 
 
Jessica K. Altman, Jamie Koprivnikar, James K. McCloskey, et al.
The study authors' cumulative clinical data suggest, that the time-limited single-agent treatment with aspacytarabine is safe and efficacious as 1st-line therapy for patients who are unfit for intensive chemotherapy. This may establish it as a new tolerable backbone in AML chemotherapy. Clinical trial information: NCT03435848
 
 
Mark J. Levis, Catherine Choy Smith, Alexander E. Perl, et al.
The study authors conclude, that the FF-10101-01 FLT3 inhibitor(50-75 mg BID ) has shown activity in patients with refractory/relapsed AML. This includes patients with activating FLT3-ITD mutations resistant to gilteritinib and other FLT3 kinase inhibitors. The treatment was well tolerated and resulted in sustained FLT3 inhibition. Clinical trial information: NCT03194685